Aurobindo Pharma Ltd
BSE:524804

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
BSE:524804
Watchlist
Price: 1 150.55 INR 0.91% Market Closed
Market Cap: ₹674.2B

Operating Margin

15.3%
Current
Improving
by 1.6%
vs 3-y average of 13.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
15.3%
=
Operating Income
₹49.8B
/
Revenue
₹325.1B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
15.3%
=
Operating Income
₹49.8B
/
Revenue
₹325.1B

Peer Comparison

Country Company Market Cap Operating
Margin
IN
Aurobindo Pharma Ltd
NSE:AUROPHARMA
697.1B INR
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.7B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.7B EUR
Loading...

Market Distribution

Higher than 75% of companies in India
Percentile
75th
Based on 5 437 companies
75th percentile
15.3%
Low
-153 833.3% — 2.7%
Typical Range
2.7% — 13.2%
High
13.2% — 9 977%
Distribution Statistics
India
Min -153 833.3%
30th Percentile 2.7%
Median 7.3%
70th Percentile 13.2%
Max 9 977%

Aurobindo Pharma Ltd
Glance View

Aurobindo Pharma Ltd., founded in 1986 by P.V. Ramprasad Reddy and K. Nityananda Reddy, began its journey in the bustling pharmaceutical landscape of Hyderabad, India. Initially starting as a provider of semi-synthetic penicillin, the company gradually diversified its product portfolio across major therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, and anti-diabetics, among others. With an entrepreneurial vision, Aurobindo leveraged vertical integration to optimize costs and operations—manufacturing everything from raw active pharmaceutical ingredients (APIs) to finished dosage formulations. This strategic approach not only reinforced its cost-leadership position but also enabled the company to meet stringent regulatory requirements in global markets, providing them a competitive edge. In its quest for expansion, Aurobindo penetrated international markets, including the United States and Europe, through acquisitions and strategic alliances, expanding its manufacturing capabilities and distribution networks. The company generates its revenue primarily through the sale of generic pharmaceuticals, which are manufactured in their state-of-the-art facilities and sold worldwide. Aurobindo's robust research and development (R&D) investments have further fueled its growth by enabling the company to introduce new and complex product lines, including biosimilars and specialty generics. This blend of strategic foresight, operational excellence, and commitment to innovation is what propels Aurobindo Pharma's ongoing narrative in the global pharmaceutical industry.

AUROPHARMA Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
15.3%
=
Operating Income
₹49.8B
/
Revenue
₹325.1B
What is Aurobindo Pharma Ltd's current Operating Margin?

The current Operating Margin for Aurobindo Pharma Ltd is 15.3%, which is above its 3-year median of 13.7%.

How has Operating Margin changed over time?

Over the last 3 years, Aurobindo Pharma Ltd’s Operating Margin has increased from 10.7% to 15.3%. During this period, it reached a low of 10% on Dec 31, 2022 and a high of 16.2% on Sep 30, 2024.

Back to Top